We are back for Day 2 of the 2026 Milton Wexler Biennial Symposium in Boston, Massachusetts, with the Huntington’s Disease Foundation. Today’s scientific talks covered a range of topics, from somatic ...

As with other shared clinical datasets, participant identities remain protected through secure coding and anonymisation.

Roche’s news also reminds us of a broader challenge. Many of today’s genetic therapies are scientifically remarkable, but ...

On 25th June 2024, Wave Life Sciences shared the results of their SELECT-HD clinical trialclinical trial Very carefully planned experiments designed to answer specific questions about how a drug ...

In plain language. Written by scientists. Huntington’s disease disrupts genetic "traffic lights," keeping genes green when they should be red. These genetic traffic jams may act to speed brain cell ...

In plain language. Written by scientists. Advanced Care Planning is a tool that can allow people living with Huntington’s disease to compassionately engage with loved ones about their future care, ...

In plain language. Written by scientists. ⏱️10min read | Roche’s decision to stop development of 2 HTT-lowering programmes is disappointing, but the story doesn’t end there. Years of research answered ...

In plain language. Written by scientists. #Buzzilia, day 4: Jeff and Ed's roundup of happenings from the closing day of the HD World Congress in Rio de Janeiro #Buzzilia, day 3: Jeff and Ed's roundup ...

8 min read | July was a hard month for Huntington’s disease research, with Roche ending two HD programs. But the month also brought promising new tools, a new player in somatic expansion, and ...

Huntington’s disease (HD) involves the loss of cells in the striatum, an area of the brain that plays important roles in movement, cognition, and behaviour. For decades, researchers have been ...